This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Paclitaxel + cisplatin cost effective in NSCLC. Pharmacoecon. Outcomes News 230, 8 (1999). https://doi.org/10.1007/BF03275103
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275103